HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder - PubMed (original) (raw)

HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder

Z Latif et al. Br J Cancer. 2003.

Abstract

The mortality from transitional cell carcinoma (TCC) of the urinary bladder increases significantly with the progression of superficial or locally invasive disease (pTa/pT1) to detrusor muscle-invasive disease (pT2+). The most common prognostic markers in clinical use are tumour stage and grade, which are subject to considerable intra- and interobserver variation. Polysomy 17 and HER2/neu gene amplification and protein overexpression have been associated with more advanced disease. Standardised techniques of fluorescence in situ hybridisation and immunohistochemistry, which are currently applied to other cancers with a view to offering anti-HER2/neu therapies, were applied to tumour pairs comprising pre- and postinvasive disease from 25 patients undergoing treatment for bladder cancer. In the preinvasive tumours, increased HER2/neu copy number was observed in 76% of cases and increased chromosome 17 copy number in 88% of cases, and in the postinvasive group these values were 92 and 96%, respectively (not significantly different P=0.09 and 0.07, respectively). HER2 gene amplification rates were 8% in both groups. Protein overexpression rates were 76 and 52%, respectively, in the pre- and postinvasive groups (P=0.06). These results suggest that HER2/neu abnormalities occur prior to and persist with the onset of muscle-invasive disease. Gene amplification is uncommon and other molecular mechanisms must account for the high rates of protein overexpression. Anti-HER2/neu therapy might be of use in the treatment of TCC.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Bae CD, Juhnn YS, Park JB (2001) Post-transcriptional control of c-erb B2 overexpression in stomach cancer cells. Exp Mol Med 37(1): 15–19 - PubMed
    1. Bartlett JMS, Adie L, Watters AD, Going JJ, Grigor KM (1999) Chromosomal aberrations in transitional cell carcinoma that are predictive of disease outcome are independent of polyploidy. Br J Urol Int 84(7): 775–779 - PubMed
    1. Bartlett JMS, Watters AD, Ballantyne SA, Going JJ, Grigor KM, Cooke TG (1998) Is chromosome 9 loss a marker of disease recurrence in transitional cell carcinoma of the urinary bladder? Br J Cancer 77(12): 2193–2198 - PMC - PubMed
    1. Bartlett JM, Goint JJ, Mallon EA, Reeves JR, Stanton P, Richmond J, Donald B, Ferrier R, Cooke TG (2001) Evaluating her 2 amplification and overexpression in breast cancer. J path 195(4): 422–428 - PubMed
    1. Baselga J (2001) Clinical trials of Herceptin. Eur J Cancer 37: s18–s24 - PubMed

MeSH terms

Substances

LinkOut - more resources